Risk prediction scores for risk assessment of venous thromboembolism in newly diagnosed multiple myeloma
| SAVED score: applicable to patients with newly diagnosed MM starting immunomodulatory therapy . | Stratified risk groups . | ||
|---|---|---|---|
| Surgery within last 90 days | +2 | Low risk: | score ≤1 |
| Asian race | –3 | High risk: | score ≥2 |
| VTE history | +3 | ||
| Eighty (age ≥80 years) | +1 | ||
| Dexamethasone (high dose) | +2 | ||
| Dexamethasone (low dose) | +1 | ||
| IMPEDE VTE score: applicable to patients with newly diagnosed MM starting myeloma therapy | Stratified risk groups | ||
| Immunomodulatory drug | +4 | Low risk: | score ≤3 |
| Body Mass Index ≥25 kg/m2 | +1 | Intermediate risk: | score 4-7 |
| Pathologic fracture pelvis/femur | +4 | High risk: | score ≥8 |
| Erythropoiesis-stimulating agent | +1 | ||
| Dexamethasone (high dose) | +4 | ||
| Dexamethasone (low dose) | +2 | ||
| Doxorubicin | +3 | ||
| Ethnicity/race: Asian race | –3 | ||
| Venous thromboembolism history | +5 | ||
| Tunneled line/CVC | +2 | ||
| Existing therapeutic warfarin or LMWH use | –5 | ||
| Existing prophylactic aspirin or LMWH use | –3 | ||
| PRISM score: applicable to patients with newly diagnosed MM starting myeloma therapy | Stratified risk groups | ||
| Prior history of venous thromboembolism | +8 | Low risk: | score 0 |
| Race: Black race | +1 | Intermediate risk: | score 1-6 |
| Immunomodulatory use in induction therapy | +2 | High risk: | score ≥7 |
| Surgery (within 90 days) | +5 | ||
| Abnormal Metaphase Cytogenetics | +2 | ||
| SAVED score: applicable to patients with newly diagnosed MM starting immunomodulatory therapy . | Stratified risk groups . | ||
|---|---|---|---|
| Surgery within last 90 days | +2 | Low risk: | score ≤1 |
| Asian race | –3 | High risk: | score ≥2 |
| VTE history | +3 | ||
| Eighty (age ≥80 years) | +1 | ||
| Dexamethasone (high dose) | +2 | ||
| Dexamethasone (low dose) | +1 | ||
| IMPEDE VTE score: applicable to patients with newly diagnosed MM starting myeloma therapy | Stratified risk groups | ||
| Immunomodulatory drug | +4 | Low risk: | score ≤3 |
| Body Mass Index ≥25 kg/m2 | +1 | Intermediate risk: | score 4-7 |
| Pathologic fracture pelvis/femur | +4 | High risk: | score ≥8 |
| Erythropoiesis-stimulating agent | +1 | ||
| Dexamethasone (high dose) | +4 | ||
| Dexamethasone (low dose) | +2 | ||
| Doxorubicin | +3 | ||
| Ethnicity/race: Asian race | –3 | ||
| Venous thromboembolism history | +5 | ||
| Tunneled line/CVC | +2 | ||
| Existing therapeutic warfarin or LMWH use | –5 | ||
| Existing prophylactic aspirin or LMWH use | –3 | ||
| PRISM score: applicable to patients with newly diagnosed MM starting myeloma therapy | Stratified risk groups | ||
| Prior history of venous thromboembolism | +8 | Low risk: | score 0 |
| Race: Black race | +1 | Intermediate risk: | score 1-6 |
| Immunomodulatory use in induction therapy | +2 | High risk: | score ≥7 |
| Surgery (within 90 days) | +5 | ||
| Abnormal Metaphase Cytogenetics | +2 | ||